Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cyclooxygenase-2 specificity and its clinical implications.

J B Lefkowith1

  • 1Research and Development, G.D. Searle and Company, Research and Development, Chicago, Illinois 60077, USA.

The American Journal of Medicine
|July 2, 1999
PubMed
Summary

Celecoxib, a COX-2 inhibitor, effectively treats pain and inflammation from arthritis. It offers relief with fewer gastrointestinal side effects compared to traditional nonsteroidal anti-inflammatory drugs (NSAIDs).

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip.

The Journal of international medical research·2002
Same author

Celecoxib versus diclofenac in the management of osteoarthritis of the knee.

Scandinavian journal of rheumatology·2001
Same author

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

JAMA·2000
Same author

Economic and gastrointestinal safety comparisons of etodolac, nabumetone, and oxaprozin from insurance claims data from patients with arthritis.

Clinical therapeutics·1999
Same author

Leukocyte migration in immune complex glomerulonephritis: role of adhesion receptors.

Kidney international·1997
Same author

Chemokines are expressed in a myeloid cell-dependent fashion and mediate distinct functions in immune complex glomerulonephritis in rat.

Journal of immunology (Baltimore, Md. : 1950)·1997

Area of Science:

  • Pharmacology
  • Rheumatology
  • Gastroenterology

Background:

  • Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) to reduce pain and inflammation.
  • COX-1 inhibition by NSAIDs causes side effects like gastric ulcers and impaired platelet function.
  • COX-2 is a key mediator of pain and inflammation.

Purpose of the Study:

  • To evaluate the efficacy and safety of celecoxib, a COX-2 specific inhibitor.
  • To assess the potential of COX-2 inhibitors to reduce gastrointestinal complications associated with NSAIDs.
  • To determine celecoxib's effectiveness in treating osteoarthritis and rheumatoid arthritis.

Main Methods:

  • Phase II and III clinical studies were conducted.
  • Efficacy was assessed for dental pain, osteoarthritis, and rheumatoid arthritis.

Related Experiment Videos

  • Safety was evaluated by comparing gastroduodenal injury rates and adverse events to NSAIDs and placebo.

    • Main Results:

    • Celecoxib demonstrated efficacy in alleviating pain and symptoms of osteoarthritis and rheumatoid arthritis.
    • Celecoxib showed a significantly lower rate of gastroduodenal injury compared to conventional NSAIDs.
    • Adverse event and withdrawal rates for celecoxib were comparable to placebo.

    Conclusions:

    • Celecoxib is a safe and effective treatment for osteoarthritis and rheumatoid arthritis.
    • COX-2 specific inhibition offers pain and inflammation relief with reduced risk of NSAID-related toxicities.
    • Celecoxib presents a promising therapeutic option for inflammatory conditions.